facility, capital expenditure of laboratory equipment, and other laboratory materials, and costs associated with securing a new office

filing / Aug 7, 2026 / receipt

for office space in Chicago, Illinois, commencing on August 1, 2023 for a term of three years and four months and expiring on November

filing / Aug 7, 2026 / receipt

facility, capital expenditure of laboratory equipment, and other laboratory materials, and costs associated with securing a new office

filing / Aug 7, 2026 / receipt

for office space in Chicago, Illinois, commencing on August 1, 2023 for a term of three years and four months and expiring on November

filing / Aug 7, 2026 / receipt

Warren Hosseinion, MD, Meeshanthini V. Dogan, Ph.D., Wendy J. Betts, Paul F. Burton, Peter K. Fung, MD, James Intrater, and Robert Philibert, MD, Ph.D. (collectively, the “Director Nominees”)

filing / Aug 5, 2026 / receipt

Meeshanthini V. Dogan, Ph.D. has served as our Chief Executive Officer and a director since inception.

filing / Aug 5, 2026 / receipt

Robert Philibert, MD., Ph.D. has served as our Chief Medical Officer and as a director since inception.

filing / Aug 5, 2026 / receipt

Warren Hosseinion, MD has served as the Company’s Non-Executive Chairman of the Board since the consummation of the Business Combination in October 2022.

filing / Aug 5, 2026 / receipt

Wendy J. Betts has served as a member of the Company’s Board of Directors since November 15, 2024.

filing / Aug 5, 2026 / receipt

Elisa Luqman, J.D., MBA 61 Chief Financial Officer

filing / Aug 5, 2026 / receipt

Timur Dogan, Ph.D. 38 Chief Technology Officer

filing / Aug 5, 2026 / receipt

Meeshanthini V. Dogan, 2025 300,000 0 0 0 12,300 (1) 312,300 CEO

filing / Aug 5, 2026 / receipt